🇺🇸 FDA
Pipeline program

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

CA061-1006

Phase 1 other active

Quick answer

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) for Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS) is a Phase 1 program (other) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)
Phase
Phase 1
Modality
other
Status
active

Clinical trials